FDA Flags Chinese Personal-Care Firm For Drug GMP Failings
This article was originally published in The Rose Sheet
Executive Summary
The agency will pursue cosmetics and personal-care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.
You may also be interested in...
FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms
When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be using one standard and that’s the drug standard, says Karyn Campbell, director of the investigations branch at FDA’s Philadelphia District Office.
FDA Working Aggressively On Globalization Strategy – Commissioner
Less than a week after the agency’s international regulatory “aggressiveness” was called into question at a Senate appropriations hearing, FDA releases its Global Engagement report, highlighting its accomplishments to date while noting that ensuring the safety of imported products is a “formidable task.”
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.